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Objectives – Vitamin D (VD) has an impact on the immune system 
via vitamin D nuclear receptor (VDR) present in various types of 
immune cells. Its anti-angiogenic, pro-apoptotic, and anti-prolifer-
ative effect have been found as well. We investigated VD status of 
paediatric patients with malignant disease such as leukaemia, lym-
phoma, Langerhans cell histiocytosis, and solid malignant tumours. 
Materials and Methods – In children with malignant disease from 
the case cohort, total 41, serum VD level was measured upon first 
admission to the hospital. They were subdivided into those with 
leukaemia / lymphoma and those with solid malignant tumours 
(body and central nervous system). Langerhans cell histiocytosis 
was included in leukaemia /lymphoma group. The optimal level for 
VD was recommended to be >75 nmol/L. The insufficiency was 
presented with levels of 25-OH VD between 50 and 75 nmol/L, 
while levels ≤50 nmol/L were recognized as deficiency. We further 
categorized deficiency as strong (30 – 49.9 nmol/L), significant (20 
– 29.9 nmol/L) and extreme (<20 nmol/L). Results – Only three 
patients had optimal level of VD. All others (92.8%) suffered from 
VD insufficiency 11 (26.8%) and various levels of deficiency: 10 
(24.4%) from strong, 11 (26.8%) significant, and 6 (14.6%) from 
extreme. Conclusions – The prevalence of VD insufficiency/defi-
ciency in paediatric patients with malignant disease is very high 
especially in patients with solid malignant tumour. Such condition, 
regarding that VD insufficiency/deficiency can debilitate immune 
system may have a negative impact on these patients.
Introduction
Vitamin D (VD) has an important role in 
regulation of serum calcium and phospho-
rus concentrations. In addition, it has a very 
important extra skeletal role mediating and 
enhancing the immune system action (1). Its 
biological action is achieved by binding to a 
vitamin D nuclear receptor (VDR) present in 
nearly all types of immune cells, spanning the 
innate and adaptive immune response (2). 
VD is a strong immunological modulator. It 
also has anti-proliferative effects, potentiate 
apoptosis, and inhibit angiogenesis (3). Its 
serum level is the best indicator of overall vi-
tamin status because its measurement reflects 
total VD in the body. Among healthy chil-
dren and adolescents in the United States, the 
prevalence of vitamin D deficiency (VDD) is 
9%–18%, while among critically ill children 
rates are 35%–70% (4-8). Those, at greatest 
risk of VDD, include patients with chronic 
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illnesses (e.g. chronic kidney disease (CKD), 
cystic fibrosis (CF), asthma, and sickle cell 
disease), dark-pigmented skin, poor nutri-
tion, and infants who are exclusively breast-
fed (9, 10). An increasing body of evidence 
demonstrates an association between several 
VDR gene polymorphisms and cancer risk 
and progression (11). Research in animals 
has shown that severe VDD or deletion of 
the VDR increases cancer risk (12).
In this study, we investigated the VD sta-
tus of paediatric patients diagnosed with a 
malignancy. We correlated the data with pa-
tients’ gender, and cancer type.
Materials and Methods
Subjects
Children from the case cohort were recruited 
from patients newly diagnosed with malig-
nancy and hospitalized and treated from 
1 January 2012 until 20 April 2015 at the 
Paediatric Haematology/Oncology Division, 
Department of Paediatrics, University Hos-
pital of Split. Children were excluded from 
the study if they were on VD supplemen-
tation. Patients were subdivided into those 
with leukaemia/lymphoma and those with 
solid malignant tumour (body and central 
nervous system). The patients with Langer-
hans cell histiocytosis (LCH) were included 
in leukaemia/lymphoma group. As a control 
group, we used randomly selected healthy pa-
tients admitted to Department of Paediatric 
Surgery for elective one-day minor operation 
in the period from June 12th, 2015 until 
June 23rd, 2015. Research was conducted 
as case-control study. Data collected on the 
demographic information of our patients in-
cluded age and gender. Data were also col-
lected on disease characteristics of the study 
population. 
Determination f Serum 25-Hydroxy 
Vitamin D Levels
Participants from patient and control group 
provided a blood sample for 25-hydroxyvita-
min D determination, which is the standard 
indicator of VD status (19). All of the pa-
tients had their blood drawn upon first ad-
mission to our division. Venous blood sam-
ple was collected using standard sampling 
tubes or tubes containing separating gel. Af-
ter that, serum was separated for the analysis. 
Serum VD level was measured using a com-
mercially available Elecsys® Vitamin D total 
assay (Roche Diagnostics International Ltd., 
Rotkreuz, Switzerland). The assay used is in-
tended for the quantitative determination of 
VD using competitive electrochemiluminis-
cence binding technique. Measuring range 
of the test is 7.5-175 nmol/L. There is no 
standard definition or consensus about the 
optimal VD status in children. The preferred 
and optimal level for VD is recommended to 
be >75 nmol/L (13, 14). VD insufficiency is 
present with levels of 25-OH VD between 
50 and 75 nmol/L, while levels ≤50 nmol/L 
are considered inadequate and reflect a state 
of deficiency. We further categorized VD 
deficiency as strong (30–49.9 nmol/L), sig-
nificant (20–29.9 nmol/L) or extreme (<20 
nmol/L) (20).
Ethics Statement
The study was approved by the University 
Hospital of Split Ethics Committee and the 
children parents submitted informed written 
consent for their participation in the study 
and the collection of the data from their 
medical charts.
Statistical Analyses
Data are presented as individual data points 
and medians. Comparison of groups is based 
on Kruskal-Wallis and Dunn’s multiple com-
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parison test. All applied test were two-tailed, 
and the results were considered as a statisti-
cally significant if P value was less or equal 
0.05.
Results
In the analysed period, 41 children were ad-
mitted at the Department of Paediatrics with 
newly diagnosed malignant disease. Out of 
them, 20 were females and 21 were males. 
The mean age at the time of blood draw was 
115.6 months (SD=65.3 months). VD was 
significantly low in sick girls then in boys 
(Mann-Whitney U-test, P=0.010). Median 
value for girls was 26.8 nmol/L, and 49.2 
nmol/L for boys. Patient’s diagnosis and the 
level of VD are presented in Table 1 and Fig. 
1 and 2, while the distribution of VD level 
(by category) in patients with specific tu-
mour type is presented in Table 2. 
The majority of patients suffered from 
acute lymphoblastic leukaemia (ALL), acute 
myeloid leukaemia (AML), lymphoma and 
LCH. Only three patients had optimal lev-
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Fig. 1. Patient’s Diagnosis and the Level of VD.
Table 1. Patient’s Diagnosis 
Tumour type
Patients
N (%)
Acute lymphoblastic leukaemia 16 (39)
Acute myeloid leukaemia 3 (7.3)
Lymphoma 4 (9.8)
Langerhans cell histiocytosis 6 (14.6)
Solid tumours* 12 (29.3)
*Astrocytoma, Neuroblastoma, Ewing sarcoma, Medulloblas-
toma, Dysgerminoma Ovarii, Yolk Sac, Tumour mixtus testis 
and Juvenile Granulosa Cell Tumour.
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el of VD (two patients suffering from ALL 
and one patient suffering from tumour mix-
tus testis). All others (92.8%) suffered from 
various level of VD insufficiency / deficiency. 
Out of those 10 (24.4%) had a strong, 11 
(26.8%) had a significant, and 6 (14.6%) 
had an extreme VD deficiency. The mean 
concentration of VD in control group was 
53.2±30.2 nmol/L (mean±SD), there is no 
statistical difference versus leukaemia/lym-
phoma (41.6±20.1 nmol/L), and solid tu-
mours group (34.9±20.0) (Fig. 2). However, 
in the solid tumours group the mean value 
of VD was in average 18.26 nmol/L lower in 
comparison to control group.
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Fig. 2. Patient’s Diagnosis and the Level of VD for Pooled Groups.
Table 2. Distribution of Vitamin D Level (by category) in Patients with Specific Tumour Type
Vitamin D level by  
categories ALL
Number of patients by tumour type and category of vitamin D level
AML LYPH LCH MB Other ST Total (%)
Optimal 2 - - - - 1 3 (7.3)
Insufficiency 3 - 3 3 - 2* 11 (26.8)
Deficiency Strong 6 1 - - 3† 10 (24.4)
Significant 3 1 1 3 1 2‡ 11 (26.8)
Extreme 2 1 - - 1 2§ 6 (14.7)
Optimal >75 nmol/L; Insufficiency between 50 and 75 nmol/L; Deficiency: Strong 30-49.9 nmol/L; Significant: 20-29.9 
nmol/L; Extreme: <20 nmol/L.ALL=Acute Lymphoblastic Leukaemia; AML=Acute Myeloid Leukaemia; LYPH=Lymphoma; 
LCH=Langerhans cell histiocytosis; MB=Medulloblastoma; ST=Solid Tumour:*Neuroblastoma; †Ganglioma Astrocytoma; ‡Dys-
germinoma Ovarii and Ewing Sarcoma; §Yolk Sac and Juvenile Granulosa Cell Tumour.
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Discussion
The results of this study showed that vast ma-
jority (92.8%) of our newly diagnosed paedi-
atric haemato-oncology patients and control 
group have decreased VD levels. This finding 
was not expected since all the participants in 
this study live in southern part of Croatia, 
along the Adriatic Coast with many sunny 
days per year. 
There are studies, which indicate that 
most of the children with cancer show some 
degree of VDD at diagnosis or develop defi-
ciency during therapy (15-18). VDD is also 
prevalent in survivors of paediatric ALL (19). 
We do not know the reason why our patients 
have so high prevalence of VD insufficiency/
deficiency at time of diagnosis. It is very 
likely that paediatric oncology patients are at 
risk for developing deficiency. During their 
treatment it is expected that they will have 
poor nutrition, and that their appetite will 
be affected leading to decreased oral intake of 
dietary VD (21). In addition, they will prob-
ably lack sun exposure due to treatment and 
seasonal or climate variations (21). As corti-
costeroids are integral part of treatment in 
some forms of paediatric cancer, it is impor-
tant to recognize whether patients have VD 
insufficiency or VDD (22). This is important 
since these factors contribute to increased 
risk for osteopenia/osteoporosis and can have 
the impact to disease outcome. All the blood 
samples in our patients were drawn at the 
time of admission when the malignancy di-
agnosis was set, and it can be assumed that 
this is not entirely due to the poor nutrition 
and definitely not a consequence of the che-
motherapy or corticosteroid treatment. What 
is happening with immune system during 
VDD? Can it contribute to onset of malig-
nant disease? There are so many questions to 
ask and the science in further investigation 
may give us the answer. There are also other 
risk factors contributing to VDD in child-
hood malignancies, like malaise and fatigue 
leading to more indoor activities, low levels 
of active VD due to renal or hepatic involve-
ment of the disease, genetic factors, obesity, 
mucositis leading to limited absorption of 
VD, drug – VD interactions (3, 23, 24). 
Although there are only rare studies eval-
uating the VD levels in patients with pae-
diatric malignancies, our results are similar 
to others previously reported. Significantly, 
lower VD levels were found in children 
with solid tumours and leukaemia and lym-
phomas compared to the control group of 
healthy subjects (17). Suboptimal VD levels 
were found as common in paediatric patients 
scheduled to receive haematopoietic stem 
cell transplantation and were associated with 
lower overall 1-year survival (25). Therefore, 
since some studies have indicated that VD 
may have beneficial impact on survival fol-
lowing cancer it is important to assess VD 
levels in patients and to start VD supplemen-
tation when needed (26, 27). This could be 
achieved by including VD in recommended 
bundle of tests for paediatric haemato-oncol-
ogy patients. The connection between VD 
and infections or sepsis supports this need 
especially because it was found that VDD 
patients treated in intensive care units have 
higher mortality (28). That was also con-
firmed by meta-analysis which suggested that 
VDD increases susceptibility for severe infec-
tions and mortality of the critically ill (29).
Limitation of the Study
This study has some limitations, which have 
to be pointed out. The first one is the lim-
ited patient population studied. Larger series 
with long-term follow-up are needed to con-
firm our conclusions. Finally, our study did 
not compare results of the malignant disease 
treatment with or without VD supplementa-
tion. The major weakness of this study is that 
our control group is very small so we do not 
know if those with malignancy were more 
at risk for VD deficiency than healthy chil-
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dren of the same age and gender. However, 
our preliminary results will be the subject of 
ongoing studies and our limitation may be 
someone else’s inspiration for the new study.
Conclusion
In conclusion, children with cancer are defi-
nitely at risk of having VDD and adequate 
replacement should be started as soon as ma-
lignancy has been diagnosed to avoid further 
VD level decrease. However, further studies 
are warranted to determine the full poten-
tial role of VD to disease outcome. Hence, 
measuring serum levels of VD could be con-
sidered in the routine assessment of children 
with malignant disease. We propose to un-
dertake a long-term study in the near fu-
ture in order to determine the effect of VD 
supplementation on malignancy relapse pre-
vention and to establish whether a cause and 
effect relationship exists between VD and 
malignant disease in children.
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